top of page
Search

Cosmetics GMP: 5 Assumptions Behind Recent Recalls

Nov 12
4 min read

Cosmetics GMP has moved from a nice-to-have to a regulatory expectation, and many recent cosmetic recalls trace back to assumptions that no longer hold. In the United States, the Modernization of Cosmetics Regulation Act (MoCRA) gives the FDA new authority over cosmetic manufacturers, including mandatory recall powers, facility registration, product listing and safety substantiation. Internationally, ISO 22716 sets the recognised cosmetics GMP framework. Against that backdrop, the beliefs that once let a brand run lightly on quality are exactly the beliefs that now lead to recalls. This article sets out five of them and how to close each one.


Controlled manufacturing environment for GMP compliant cosmetic production

None of these assumptions is unreasonable on its face. Each was defensible when cosmetics sat outside a strong GMP regime. The problem is that the regulatory ground has shifted, and product quality expectations have risen with it.


Why cosmetics GMP assumptions now carry recall risk

A recall is rarely caused by a single mistake at the bench. It is usually the visible end of a chain that started with a decision not to build a control, because the risk felt remote or the standard felt optional. Microbial contamination, undeclared or prohibited ingredients, mislabeling and inadequate safety substantiation are recurring themes behind cosmetic recalls, and each maps back to a GMP control that was assumed unnecessary.


Under MoCRA, the cost of that gap is higher than it used to be. The FDA can now compel a recall rather than rely on a company volunteering one, and facilities are visible through registration and product listing. Cosmetics GMP is now the baseline an FDA or partner audit is measured against, so an untested assumption is a live exposure.


The 5 assumptions behind recent cosmetic recalls

  • "Cosmetics are low risk, so GMP is optional." This is the root assumption. MoCRA directs the FDA to establish cosmetics GMP requirements, and ISO 22716 already defines them. Treating GMP as optional leaves a site without the batch records, controls and traceability needed to defend a product or execute a clean recall.

  • "Microbial contamination is not a real concern for cosmetics." Water-based and natural products are vulnerable to microbial growth, and preservative systems fail when they are not verified. Inadequate microbial control and preservative efficacy testing are recurring causes of cosmetic recalls, particularly for leave-on and eye-area products.

  • "Our contract manufacturer handles compliance, so we do not need oversight." Brand owners carry responsibility for the products they place on the market. Without vendor qualification, specifications and ongoing oversight, a brand inherits its contract manufacturer's weakest control and often discovers it only at recall.

  • "Labeling and claims are marketing, not compliance." The line between a cosmetic and a drug claim is a regulatory line, not a creative one. Claims that cross into drug territory, along with undeclared allergens or prohibited and restricted ingredients, are a well-documented trigger for enforcement and recall.

  • "A voluntary standard means we can self-certify without evidence." ISO 22716 and MoCRA expectations are built on documented evidence: batch records, stability data, safety substantiation and change control. Self-declaring compliance without that evidence does not survive an audit and does not support a defensible recall decision.


How to close the gaps before they become a recall

The correction for all five assumptions is the same in shape: treat cosmetics GMP as a real quality system, sized to the risk of the product. That means qualified suppliers, controlled formulations and processes, verified preservative systems, accurate labeling and claims, and documentation that would stand up in an FDA or partner audit.


Start with a gap assessment against ISO 22716 and MoCRA expectations, so you know which controls exist, which are assumed, and which are missing. Prioritise the controls tied to the highest-risk products and claims. Build vendor oversight into your quality system rather than leaving it to a contract. A structured cosmetic compliance review will map your current state to the standard, GMP risk and due diligence work will surface the supplier and contract exposures before an auditor does, and regulatory readiness support will prepare the site for the inspections MoCRA makes more likely. Where gaps are already open, GMP remediation turns them into closed, evidenced controls.


Closing these gaps is not only about avoiding a recall. It is about being able to prove, on demand, that your products are made and controlled the way the market now expects.


Frequently asked questions

Does MoCRA require cosmetics GMP?

MoCRA directs the FDA to establish good manufacturing practice requirements for cosmetics and gives the agency new authority, including mandatory recall power, facility registration and product listing. GMP is central to how the FDA is expected to hold cosmetic manufacturers to account, so building to a recognised cosmetics GMP standard is the practical way to prepare.


What is ISO 22716?

ISO 22716 is the international standard for cosmetics good manufacturing practice. It covers production, control, storage and shipment of cosmetic products, including personnel, premises, equipment, raw materials, production, finished products, quality control, documentation and handling of complaints and recalls. It is the most widely recognised framework for cosmetics GMP.


What most often causes a cosmetic recall?

Common causes include microbial contamination and preservative failure, undeclared or prohibited ingredients, mislabeling and claims that cross into drug territory, and inadequate safety substantiation. Each of these maps back to a GMP control that a site can build and verify in advance.


Is a brand owner responsible if a contract manufacturer makes the product?

Yes. Using a contract manufacturer does not transfer responsibility for the product. Brand owners need to qualify their suppliers, set clear specifications and maintain ongoing oversight so that the products placed on the market are controlled and defensible.


Kieran Falvey is Founder and Managing Director of Pharmalliance Consulting Ltd and the creator of Contamination Control by Design (CCbD). He has more than 20 years designing, building and running pharmaceutical facilities worldwide, across FDA, EMA, TGA, PIC/S and Indian FDA (CDSCO) jurisdictions. Global expert in cGMP Compliance, Remediation and Contamination Control, helping Sterile, Non-Sterile, ATMP and Cosmetic companies navigate cGMP compliance issues.


Pharmalliance Consulting is a GMP compliance consultancy serving pharmaceutical, sterile, non-sterile, OSD, ATMP and cosmetic manufacturers in Ireland, the UK, the EU and the US. It helps sites identify and remediate GMP risks across facilities, quality systems and contamination control, aligned with HPRA, MHRA, EMA and FDA expectations, turning findings into defensible, inspection-ready practice.


If you make or own a cosmetic brand, Pharmalliance can test your quality system against ISO 22716 and MoCRA expectations before a recall or audit does. Talk to us about a cosmetic compliance review.

 
 
 

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page